The company’s Phase I candidate for traveller’s diarrhea will be the initial focus of the partnership.
Ace BioSciences will aid PATH in its efforts to create a vaccine against bacterial diarrhea for the developing world. The focus will be on developing temperature-stable ETEC (enterotoxigenic E. Coli) vaccine formulations.
Funding for the research will come from PATH’s Enteric Vaccine Initiative. Ace Biosciences will collaborate with PATH’s Vaccine Stabilization Project team to develop dry and temperature-stable ETEC vaccine candidates.
The pilot studies will use Ace BioSciences’ live, whole-cell oral vaccine candidate. ACE527, which the company is developing as a vaccine for traveller’s diarrhea, comprises three attenuated ETEC strains. Ace Biosciences reports that five Phase I trials have demonstrated safety and immunogenicity.